EHA 2024: Updates in the Treatment of CLL   

Key opinion leaders are introduced and present a concise overview of the topics to be addressed.

Leading chronic lymphocytic leukemia specialists explore strategies for selecting initial treatments, weighing the merits of fixed-duration versus continuous Bruton's tyrosine kinase inhibitor (BTKi) therapy for newly diagnosed patients.

Key opinion leaders examine the use of continuous Bruton's tyrosine kinase inhibitor therapy in front-line treatment, strategies for sequencing therapies, and the potential incorporation of obinutuzumab into treatment regimens.

The panelists explore strategies for managing front-line chronic lymphocytic leukemia (CLL) treatment in patients with pre-existing hypertension and atrial fibrillation.

A chronic lymphocytic leukemia expert examines patient criteria for first-line doublet therapy (venetoclax plus BTK inhibitor) versus triplet therapy, while also addressing findings from the CAPTIVATE trial.

Experts analyze the potential applications of triplet therapy (venetoclax, BTK inhibitor, and obinutuzumab) in first-line chronic lymphocytic leukemia treatment, focusing on patient subgroups most likely to benefit from this approach.

An expert in the field provides insights into current clinical trials investigating the efficacy of combined BCL-2 inhibitor and BTK inhibitor therapies.

A clinician outlines their treatment strategy for relapsed/refractory chronic lymphocytic leukemia patients, emphasizing how previous treatment history influences subsequent therapy choices.

A panel of experts examines and interprets the most recent matching-adjusted indirect comparison (MAIC) data presented at the European Hematology Association 2024 conference, focusing on the comparative analysis of the ASCEND and ALPINE trials in chronic lymphocytic leukemia treatment.

Key opinion leaders compare and contrast the most frequently observed causes of BTK inhibitor intolerance in clinical practice among patients treated with ibrutinib, acalabrutinib, or zanubrutinib.

Experts analyze recent real-world evidence on treatment patterns, focusing on the strategies and outcomes of switching and sequencing therapies in chronic lymphocytic leukemia patients.

Medical experts deliberate on strategies for managing newly developed or exacerbated hypertension in patients undergoing treatment with BTK inhibitors for chronic lymphocytic leukemia.

An oncology specialist outlines their general approach to managing treatment-related atrial fibrillation in patients receiving BTK inhibitor therapy, incorporating insights from recent clinical data to inform their management strategies.

Key opinion leaders examine recent evidence on acquired BTK inhibitor resistance in chronic lymphocytic leukemia and analyze its implications for treatment sequencing decisions in clinical practice.

A medical expert offers commentary on the recent FDA accelerated approval of pirtobrutinib, discussing the implications of the BRUIN trial findings that supported this decision for chronic lymphocytic leukemia treatment.

Key opinion leaders analyze the implications of the FDA's accelerated approval for lisocabtagene maraleucel (liso-cel) in chronic lymphocytic leukemia, based on promising results from the TRANSCEND CLL 004 trial.

The panel explores potential applications and impact of BTK inhibitor degraders as an emerging class of novel agents for treating relapsed/refractory chronic lymphocytic leukemia.

Key opinion leaders analyze the potential significance of preliminary data on BGB-16673, a BTK inhibitor degrader, in anticipation of its presentation at EHA 2024.

Nicole Lamanna, MD, offers expert insights on the emerging data for second-generation BCL2 inhibitors in relapsed/refractory chronic lymphocytic leukemia, highlighting recent advancements in the field.

Key opinion leaders provide concise insights on the potential of bispecific antibodies as emerging novel therapeutic agents for relapsed/refractory chronic lymphocytic leukemia.

The panel concludes by offering final thoughts and insights on recent advancements from EHA 2024.